New drug cocktail aims to beat tough lymphoma
NCT ID NCT07371923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who have high-risk features. About 50 participants will receive the combination for six cycles. The main goal is to see how many achieve a complete remission (no cancer detected).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (a BTK inhibitor) combined with polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone
What this could lead to
If successful, this could offer a more effective first-line treatment for high-risk DLBCL patients, potentially improving remission rates and reducing relapse.
What could go wrong
This is a small, early-phase (phase 2) single-center trial with no control group, so results may not be generalizable. The combination also carries risks of increased side effects from multiple drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••